The Journal of Immunology, Vol 154, Issue 8 3941-3951, Copyright © 1995 by American Association of Immunologists

ARTICLES

Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor

L Gorelik, M Rubin, A Prokhorova and MB Mokyr
Department of Microbiology and Immunology, University of Illinois at Chicago, 60680, USA.

We have previously shown the importance of the acquisition of CD8+ T cell-dependent tumor-eradicating immunity for the curative effectiveness of low dose melphalan (L-PAM, L-phenylalanine mustard) for mice bearing a large MOPC-315 tumor. Here we show the importance of TNF production for the curative effectiveness of low dose L-PAM for such tumor-bearing mice. Studies regarding the mechanism(s) through which TNF exerts its antitumor effects in L-PAM-treated MOPC-315 tumor- bearing mice (L-PAM TuB mice) revealed that MOPC-315 tumor cells are not sensitive to the cytotoxic effects of TNF either before or after the chemotherapy. However, TNF is essential for the in vitro generation of potent CTL activity by CD8+ T cells from L-PAM TuB mice. Moreover, addition of exogenous TNF to in vitro stimulation cultures of spleen cells from untreated mice bearing a large MOPC-315 tumor resulted in the generation of a greatly enhanced CTL activity against MOPC-315- associated Ags. Finally, we have previously shown that TCR V beta 8+/CD8+ T cells are involved in the curative effectiveness of low dose L-PAM for mice bearing a large MOPC-315 tumor. Here we show that TNF is important for the ability of MOPC-315-specific V beta 8+/CD8+ T cell lines from L-PAM TuB mice to bring about tumor eradication upon adoptive transfer into tumor-bearing mice. Taken together, these studies illustrate that low dose L-PAM mediates its therapeutic effectiveness for mice bearing a large MOPC-315 tumor, at least in part, via TNF production (e.g., by V beta 8+/CD8+ T cells), which in turn promotes the generation of anti-MOPC-315 CTL activity.

This article has been cited by other articles:

				V. M. Jovasevic and M. B. Mokyr Melphalan-Induced Expression of IFN-{beta} in MOPC-315 Tumor-Bearing Mice and Its Importance for the Up-Regulation of TNF-{alpha} Expression J. Immunol., November 1, 2001; 167(9): 4895 - 4901. [Abstract] [Full Text] [PDF]

				D. K. Sojka, M. Donepudi, J. A. Bluestone, and M. B. Mokyr Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells J. Immunol., June 15, 2000; 164(12): 6230 - 6236. [Abstract] [Full Text] [PDF]

				V. V. Kalinichenko, M. B. Mokyr, L. H. Graf Jr., R. L. Cohen, and D. A. Chambers Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a {beta}-Adrenergic Receptor Mechanism and Decreased TNF-{alpha} Gene Expression J. Immunol., September 1, 1999; 163(5): 2492 - 2499. [Abstract] [Full Text] [PDF]

				B. E. C. Plaat, W. M. Molenaar, M. F. Mastik, J. Koudstaal, E. v. den Berg, H. S. Koops, and H. J. Hoekstra Hyperthermic Isolated Limb Perfusion with Tumor Necrosis Factor-{{alpha}} and Melphalan in Patients with Locally Advanced Soft Tissue Sarcomas: Treatment Response and Clinical Outcome Related to Changes in Proliferation and Apoptosis Clin. Cancer Res., July 1, 1999; 5(7): 1650 - 1657. [Abstract] [Full Text] [PDF]

				B. Balasa, J. D. Davies, J. Lee, A. Good, B. T. Yeung, and N. Sarvetnick IL-10 Impacts Autoimmune Diabetes Via a CD8+ T Cell Pathway Circumventing the Requirement for CD4+ T and B Lymphocytes J. Immunol., October 15, 1998; 161(8): 4420 - 4427. [Abstract] [Full Text] [PDF]

				M. B. Mokyr, T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone Importance of the B7-2 Molecule for Low Dose Melphalan-Induced Acquisition of Tumor-Eradicating Immunity by Mice Bearing a Large MOPC-315 Tumor J. Immunol., February 15, 1998; 160(4): 1866 - 1874. [Abstract] [Full Text] [PDF]